‘Living’ cells in breast milk may provide clues to cancer risk, researchers say

Magnetic resonance imaging of the breast showing breast cancer. New research suggests cells harvested from breast milk may provide clues to cancer development. Photo by Nevit Dilmen/Wikimedia

Jan. 28 (UPI) — Researchers at the University of Cambridge in England have harvested living cells from human breast milk that could be used identify those at risk for developing breast cancer, they said in a paper published Friday by Nature Communications.

The cells found in human milk, once thought to be dead or dying, are living and provide a platform for the study of how breast tissue changes during lactation, the researchers said.

“By studying human milk cells, we will be able to answer some of the most fundamental questions around mammary gland function,” co-author Alecia-Jane Twigger said in a press release.

This includes questions such as, “How is milk produced? Why do some women struggle to make milk? and what strategies can be employed to improve breastfeeding outcomes for women?” said Twigger, a post-doctoral researcher in pharmacology at the University of Cambridge.

Breast tissue changes over the course of a lifetime, particularly during stages such as puberty, pregnancy, breastfeeding and aging, according to Johns Hopkins Medicine in Baltimore.

Earlier research has identified links between normal breast changes and cancer risk.

Twigger and her colleagues collected small breast milk samples from lactating volunteers as well as samples of non-lactating breast tissue donated by women who elected to have aesthetic breast reduction surgery.

Using genetic analysis technology, the researchers compared the composition of the collected breast tissue cells, identifying the differences between lactating and non-lactating human mammary glands, they said.

These differences could provide clues as to how some develop breast cancer later in life, the researchers said.

By collecting these samples donated by breastfeeding women, now known to contain living cells, researchers can capture dynamic cells in a non-invasive way, according to Twigger and her colleagues.

This greater ease of access to breast cells can open the door to more studies on women’s health in the future, they said.

“We hope this finding will enable future studies into the early steps of breast cancer,” co-author Walid Khaled, a lecturer in pharmacology at the University of Cambridge, said in a press release.

Triple-Negative Breast Cancer Disease Market Analysis Report 2021-2027 – Keytruda will Overtake Tecentriq in the TNBC Market – ResearchAndMarkets.com |

DUBLIN–(BUSINESS WIRE)–Jan 28, 2022–

The “Disease Analysis: Triple-Negative Breast Cancer” report has been added to ResearchAndMarkets.com’s offering.

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen and progesterone receptors, and does not involve the overexpression of human epidermal growth factor 2 (HER2). The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide. By 2027, incident and five-year prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million cases, respectively.

  • The TNBC market will experience rapid growth over the next 10 years across the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK). The primary drivers for this growth are the approval and subsequent uptake of new targeted therapies and immunotherapies. The market for TNBC is also becoming increasingly segmented by biomarker status, creating fierce competition among both approved and pipeline therapies for small patient populations.
  • There will likely be reimbursement issues as payers may initially hesitate to reimburse new treatments based on novel biomarkers. Additionally, payers may be unwilling to reimburse expensive therapies with only incremental improvements in patient outcomes.
  • Avastin’s relatively poor risk-to-benefit profile has led to removal from the US market and difficulties with reimbursement in the UK, where it was also removed from the Cancer Drugs Fund. Additionally, Avastin faces biosimilar competition following its 2019 patent expiry.
  • Abraxane is a preferred treatment regimen in cases of hypersensitivity to paclitaxel, and has demonstrated efficacy as a first- and second-line monotherapy treatment. The recent approval in combination with Tecentriq has boosted Abraxane’s clinical and commercial potential, although it is forecast to steadily lose market share after the introduction of generics in the EU in 2019 and in the US in 2022.
  • Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies for TNBC are forecast to become the best-selling class of drugs for this indication. Tecentriq in combination with Abraxane was the first immunotherapy approved for TNBC patients in the first-line setting, and Roche and Chugai are pursuing label expansions for Tecentriq in both the neoadjuvant and adjuvant settings. Although Tecentriq’s accelerated approval was in danger following the failure of the Phase III IMpassion131 trial, the FDA Oncologic Drugs Advisory Committee recently voted to maintain Tecentriq’s accelerated approval in the first-line setting pending data from the Phase III IMpassion132 trial. However, competitor Keytruda is expected to overtake Tecentriq in the first-line setting due to its wide variety of chemotherapy backbone options. After the Oncologic Drugs Advisory Committee unanimously voted to delay an approval decision pending more mature event-free survival data from the Phase III KEYNOTE-522 trial, Keytruda’s possible entry into the lucrative neoadjuvant/adjuvant market has been significantly delayed.
  • Although approved PARP inhibitors Lynparza and Talzenna are restricted to the relatively small germline BRCA1/2-mutated (gBRCAm) population, they are forecast to dominate within this patient segment. An expected label expansion into the adjuvant treatment setting for gBRCAm patients will add to Lynparza’s sales, making it one of the best-selling TNBC therapies over the next 10 years.
  • Halaven has become a standard of care for third-line and later treatment of TNBC since its approval, despite encountering challenges with reimbursement. Additionally, Halaven’s market share may increase with a potential label for use with the chemokine (C-X-C motif) receptor 4 (CXCR4) inhibitor balixafortide. The combination has received Fast Track status after showing promising early efficacy results in a Phase Ib study. The commercial potential of this combination will help to offset the decline in Halaven’s revenues caused by competition from a number of recently approved and current pipeline drugs.
  • In early 2020, Trodelvy received accelerated approval in the US for the treatment of TNBC patients who have failed at least two prior therapies, based on positive efficacy results in a Phase I/II study. Given the high unmet need and poor prognosis in this line of treatment, Trodelvy has experienced remarkably quick uptake after its launch despite the inclusion of two black box warnings on its label. The confirmatory Phase III ASCENT study was recently halted early due to evidence of strong efficacy, and the FDA granted full approval to Trodelvy in April 2021.
  • Capivasertib and Piqray are both in development in the front-line setting for the 25-30% of patients who present with phosphatase and tensin homolog (PTEN)/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/protein kinase B alpha (Akt)-altered tumors. While these novel therapies will dominate within patients in this subgroup, their overall commercial potential is limited due to the biomarker restriction. Capivasertib will likely be the first Akt inhibitor to market after late-phase competitor ipatasertib failed in the Phase III IPATunity130 trial and Roche’s subsequent decision to discontinue the Phase III IPATunity170 trial.
  • Key recent events include the FDA Oncologic Drugs Advisory Committee meeting for Keytruda’s supplemental Biologics License Application in the neoadjuvant/adjuvant setting, as well as the meeting re-examining Tecentriq’s accelerated approval in the first-line setting.
  • Key upcoming catalysts for 2021 include topline read-outs from the Phase III FORTRESS study of balixafortide and Halaven and from the Phase III OlympiA study of Lynparza.
  • The overall likelihood of approval of a Phase I breast cancer asset is 7.8%, and the average probability a drug advances from Phase III is 57.1%. Breast cancer drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

Key Topics Covered:

OVERVIEW

DISEASE BACKGROUND

  • Definition
  • Risk factors
  • Symptoms
  • Diagnosis
  • Patient segmentation
  • Prognosis

TREATMENT

  • Referral patterns
  • Operable Stage I-III TNBC
  • Inoperable Stage III TNBC
  • Recommended neoadjuvant/adjuvant chemotherapy regimens
  • Treatment guidelines for Stage IV or recurrent TNBC

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • Genentech’s Tecentriq Should Keep Its Accelerated Approval In Breast Cancer For Now, ODAC Says
  • Genentech’s Hopes For Keeping Tecentriq Breast Cancer Claim May Rest With Trial In Early Disease Recurrence
  • Gilead’s Trodelvy Gets Full Approval For TNBC
  • Gilead’s Trodelvy To Test UK Innovative Drug Pathway
  • Gilead Sciences/Immunomedics Seek EU Fast-Track For Sacituzumab Govitecan
  • Setback For Athenex, Hanmi As CRL Requests New Trial
  • Modeling Is Not a Drug Approval Pathway: Why Merck Flunked Keytruda’s TNBC Advisory Panel
  • Keytruda Takes On Tecentriq In TNBC Market
  • Centus Gets European Bevacizumab Approval
  • Samsung Bioepis Receives EU Bevacizumab Approval
  • Updated: Multiple Biosimilars To Avastin Have Launched In EU
  • Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown
  • Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • SELLAS Licenses Greater China Rights For Immunotherapies To 3D
  • Boehringer Buys Antibody-Drug Conjugates Biotech NBE For €1.18bn
  • Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs
  • Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
  • TriSalus Buys Dynavax’s Melanoma/Breast Cancer Therapy
  • AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
  • Daiichi Sankyo Partners With Syneos Health For Development Of Enhertu And Other Cancer Drugs

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

  • Approvals and subsequent uptake for new targeted therapies and immunotherapies will drive growth in the TNBC market
  • over the forecast period
  • Keytruda will overtake Tecentriq in the TNBC market during the forecast period
  • The PARP inhibitors will see significant use in the subset of TNBC patients with BRCA mutations over the forecast period
  • ADCs will dominate in the second-line and later setting over the forecast period

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • Tecentriq for Breast Cancer (April 27, 2021)
  • Tecentriq for Breast Cancer (April 23, 2021)
  • Keytruda for Breast Cancer (March 29, 2021)
  • Oral Paclitaxel for Breast Cancer (March 1, 2021)
  • Keytruda for Breast Cancer (February 9, 2021)
  • Keytruda for Breast Cancer (February 5, 2021)
  • Eganelisib for Breast Cancer (December 9, 2020)
  • Oral Paclitaxel for Breast Cancer (December 9, 2020)
  • Ipatasertib for Breast Cancer (September 30, 2020)
  • Tecentriq for Breast Cancer (September 19, 2020)
  • Tecentriq for Breast Cancer (September 19, 2020)
  • Trodelvy for Breast Cancer (September 19, 2020)
  • Tecentriq for Breast Cancer (August 6, 2020)
  • Trodelvy for Breast Cancer (July 6, 2020)
  • Tecentriq for Breast Cancer (June 18, 2020)
  • Keytruda for Breast Cancer (May 13, 2020)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

UNMET NEEDS

BIBLIOGRAPHY

For more information about this report visit https://www.researchandmarkets.com/r/7sfud8

View source version on businesswire.com:https://www.businesswire.com/news/home/20220128005213/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2022.

PUB: 01/28/2022 06:24 AM/DISC: 01/28/2022 06:24 AM

http://www.businesswire.com/news/home/20220128005213/en

Copyright Business Wire 2022.

Layanan kanker payudara Tayside dilemparkan ke dalam kekacauan oleh pengunduran diri lebih lanjut

Pasien di Tayside akan dibiarkan tanpa dokter kanker payudara setelah spesialis terakhir yang tersisa di kawasan itu, yang baru direkrut pada September, mengumumkan dia berhenti dari layanan tersebut.

Kepala kesehatan diperingatkan pada bulan November bahwa “penipisan” perawatan lokal akan menelan korban jiwa ketika kami mengungkapkan Dr Douglas Adamson akan pensiun dini bulan ini.

Dia adalah salah satu dari hanya dua spesialis kanker payudara yang tersisa di NHS Tayside.

Telah dikonfirmasi pada hari Kamis – hari kerja terakhir Dr Adamson – bahwa konsultan departemen lainnya juga telah mengundurkan diri dan diperkirakan akan pergi dalam beberapa bulan mendatang.

Spesialis tersebut baru direkrut pada bulan September setelah tiga putaran perekrutan tetapi tidak dapat melakukan tugas tertentu karena Dr Adamson adalah satu-satunya spesialis radioterapi kanker payudara dewan kesehatan.

Seorang ahli onkologi konsultan lebih lanjut yang bekerja di tempat lain dalam layanan kanker juga telah menyerahkan pengunduran diri mereka ke NHS Tayside.

Layanan dalam kekacauan

Pengungkapan itu kemungkinan akan membuat perawatan di kawasan itu ke dalam kekacauan lebih lanjut, dengan beberapa pasien sudah dikirim ke dewan kesehatan lain untuk perawatan.

Berbicara di Parlemen Skotlandia, MSP Timur Laut Michael Marra meminta Menteri Kesehatan Humza Yousaf untuk menerima layanan tersebut dalam krisis.

Michael Marra mengangkat skandal kanker payudara di Holyrood.

Dia berkata: “Saya dapat memberi tahu Parlemen dan menteri bahwa selama beberapa hari terakhir ada dua pengunduran diri konsultan onkologi lagi.

“Ini akan membuat NHS Tayside tidak memiliki spesialis onkologi kanker payudara dan kekurangan serius dalam perlindungan konsultan onkologi untuk situs tumor lainnya.

“Mengesampingkan ketidakmampuan pemerintah dan quango kesehatan yang membawa kita ke sini, saya memohon atas nama para wanita Dundee dan Tayside bahwa menteri akhirnya memperlakukan ini sebagai krisis.

“Apakah menteri akan segera turun tangan untuk menjamin pemulihan layanan penuh layanan kanker payudara di Dundee?”

Kekhawatiran dianggap sebagai ‘serangan politik’

Mr Yousaf menuduh MSP Buruh dari “serangan politik” saat ia menunjuk pekerjaan yang dilakukan oleh NHS Tayside untuk mengisi lowongan.

“Saya pikir penting untuk terlibat dalam masalah ini dengan cara yang non-partisan,” kata Yousaf.

“Saya pikir penting bagi kita untuk menempatkan para wanita dan pasien yang sangat terpengaruh oleh ini sebagai inti dari ini.

“Ketika dia bertanya apakah saya akan campur tangan, saya dapat memberinya jaminan mutlak bahwa saya, dan rekan-rekan menteri lainnya, telah sangat terlibat dalam masalah ini.”

Menteri Kesehatan Humza Yousaf dengan kepala eksekutif NHS Tayside Grant Archibald.Menteri Kesehatan Humza Yousaf dengan kepala eksekutif NHS Tayside Grant Archibald.

Sekretaris kesehatan menambahkan: “Direktur medis telah melakukan kontak dengan beberapa pusat kanker yang lebih besar di Inggris yang melaporkan tantangan serupa.

“Jadi ya, kami benar-benar akan bekerja sama dengan Tayside. Tentu saja, ini adalah situasi yang sangat disesalkan yang mereka alami.

“Ini tidak unik di Tayside, ini sangat terasa di Tayside, tetapi ini adalah masalah yang lebih luas.”

Pasien dikirim ke Aberdeen dan Glasgow

Berbicara kemudian, Mr Marra mengecam Mr Yousaf untuk menggembar-gemborkan “sebagai bagian dari solusi untuk krisis ini” perekrutan konsultan yang telah menyerahkan pemberitahuannya.

“Meskipun ada jaminan selama beberapa bulan terakhir, pasien sekarang harus melakukan perjalanan ke Aberdeen, Glasgow dan Lothians untuk perawatan,” kata Mr Marra.

“Ini adalah situasi yang tidak dapat diterima, dan ini akan menjadi wanita paling buruk dan termiskin yang paling tidak bisa bepergian.

“Kami sangat membutuhkan solusi, tetapi itu hanya dapat didasarkan pada pengakuan akan parahnya situasi.

“Mengherankan, sekretaris kesehatan gagal melakukannya sekali lagi hari ini.”

NHS Tayside mengkonfirmasi bahwa ahli onkologi medis payudara yang dipekerjakan pada bulan September telah mengindikasikan niat mereka untuk meninggalkan wilayah tersebut setelah periode pemberitahuan enam bulan “untuk mengambil peluang kerja di luar Skotlandia”.

Dewan kesehatan mengatakan semua peluang rekrutmen sudah diupayakan untuk mengatasi lowongan dengan dukungan dari Pemerintah Skotlandia.

Profesor direktur medis NHS Tayside Peter Stonebridge mengatakan dewan “tetap berkomitmen untuk memberikan layanan secara lokal, selama itu aman bagi pasien dan, dalam hal ini, membutuhkan tenaga medis spesialis yang sesuai”.

Dia menambahkan: “Dewan juga telah memberikan komitmen mutlak untuk membangun kembali layanan onkologi payudara di Tayside dan untuk itu kami sedang dalam diskusi berkelanjutan dengan tim onkologi lokal, sekolah kedokteran di Universitas Dundee dan Pemerintah Skotlandia untuk melihat semua pilihan yang tersedia terbuka untuk kita.”

Semua yang kita ketahui sejauh ini tentang skandal perawatan kanker payudara NHS Tayside

Sudah menjadi pelanggan? Masuk

[Tayside breast cancer services thrown into turmoil by further resignations]

[[text]]


TOUCH, The Black Breast Cancer Alliance, and Breastcancer.org unite for a groundbreaking new movement to advance the science for Black Breast Cancer

This unprecedented initiative is made possible by the generous support of our partners: Genentech, a member of the Roche Group, Bristol Myers Squibb, AstraZeneca, Novartis, Pfizer, Seagen, Daiichi-Sankyo, and Eisai.

About Touch, The Black Breast Cancer Alliance

Touch, The Black Breast Cancer Alliance drives the collaborative efforts of patients, survivors, advocates, advocacy organizations, health care professionals, researchers, and pharmaceutical companies to work collectively, with accountability, towards the common goal of eradicating Black Breast Cancer. Though there are numerous breast cancer advocacy groups and stakeholders, there is a dire need to bring all patients, survivors, advocates, advocacy organizations, health care professionals, researchers, and pharmaceutical companies together to serve as allies to fight Black Breast Cancer.

About Breastcancer.org

Breastcancer.org is a leading patient-focused resource for breast health and breast cancer education and support. Their mission is to engage and empower people with research, expert information, and a dynamic peer support community to help them make the best decisions for their lives. The nonprofit organization, founded in 2000 by chief medical officer Marisa C. Weiss, M.D., has reached 174 million people worldwide since its inception. Visit www.Breastcancer.org for more information.

About Genentech

Genentech was an early supporter and remains a significant funder of the When We Tri(al) movement for the inclusion of Black women in clinical trials. Genentech is committed to advancing health equity through strategic charitable giving partnerships aimed at designing lasting and innovative solutions to systemic healthcare disparities.

 


Media Contacts:

Alex Hill |Ten35 for TOUCH + Breastcancer.org | 313.213.2149 | Alex.Hill@ten35.com

Camille Johnson |Ten35 for TOUCH + Breastcancer.org | 651.443.1471 | camille.johnson@ten35.com **

Julia Bradbury berbagi ‘kemenangan kecil’ dalam perjuangannya melawan kanker payudara ‘Tidak pernah berpikir saya akan senang’ | Berita Selebriti | Showbiz & TV

Julia Bradbury, 51, sangat terbuka tentang pertempuran kanker payudaranya, dengan harapan dia dapat membantu orang lain di luar sana yang juga menderita. Presenter Countryfile menjalani mastektomi setelah didiagnosis kembali pada bulan September.

Terlepas dari kecemasannya yang “luar biasa” sebelum operasi yang dia anggap “brutal”, bintang TV itu tampaknya membuat kemajuan yang baik dalam pemulihan operasinya.

Pernah menjadi motivator, dia turun ke Twitter pada Selasa malam untuk mengingatkan orang lain bahwa mereka tidak sendirian.

“Untuk semua wanita di puncak #mastektomi, ini adalah saya beberapa minggu yang lalu,” tulisnya.

“Ini menjadi lebih mudah & saya bahkan tidak berpikir tentang merangkak di dinding lagi.

“Kemenangan kecil. Ini semua tentang kemenangan kecil.”

Dalam tweet terpisah, dia mendorong orang lain untuk berbagi lebih banyak sumber daya atau tips bermanfaat untuk sesama pasien kanker payudara.

Fans bergegas ke bagian komentar untuk memuji dia karena menjadi inspirasi dalam hal kanker.

Seseorang menulis: “Anda tidak mengenal saya, saya tidak mengenal Anda, selain dari televisi, tetapi mengirimkan harapan terbaik untuk pemulihan penuh dan umur panjang!”

Maksimalkan keuntungan Anda serta kurangi risiko Kamu dengan mesin slot online

Perangkat slot online adalah jenis permainan kasino di mana tokoh memasang taruhan serta kemudian hanya menyukai bola jatuh. Status pendaratan bola serta nilai “panas” ataupun dingin menentukan total yang Anda pertaruhkan. Anda dapat mempertunjukkan slot menggunakan suatu atau lebih nomor. Tujuannya adalah supaya bola Anda hal nomor yang Kamu pilih (biasanya 1, biasanya) sebelum waktu habis. Dalam beberapa besar kasus, publikasi yang menang adalah kombinasi tunggal ataupun ganda. Namun, pada beberapa kasus, hasilnya dapat ditentukan dengan kombinasi angka / warna bola.

Permainan slot on line bekerja dengan tips yang mirip secara permainan tradisional. slot. Semakin banyak Kita bertaruh, semakin besar peluang Anda untuk menang. Jika perangkat dirancang untuk mengizinkan beberapa putaran, dimungkinkan untuk memainkan banyak putaran dalam bermacam-macam kombinasi sebelum saat permainan selesai. Sesudah Anda menyelesaikan setiap putaran, Anda kudu memutuskan berapa banyak Anda ingin berspekulasi pada setiap taruhan.

Bonus kisaran gratis adalah opsi tambahan untuk slot online. Bonus itu diberikan kepada tokoh untuk mencoba ramalan garis hidup di mesin depo slot . Putaran gratis pula bisa menjadi cara bagi mesin slot online untuk meluluskan penghargaan kepada karet pemain yang mengangkat permainan mereka. Kasino berharap, jika tersebut cukup bermain, di dalam akhirnya mereka hendak kembali bermain untuk mendapatkan uang tunai atau hadiah yang akan membantu menyiapkan dana untuk dana operasional kasino.

Seperti yang kita sebutkan sebelumnya Di banyak hal. permainan slot online, menang adalah meteran pembayaran. Ini dikenal untuk pengukur pembayaran “jackpot”. Jackpot bisa beribu-ribu dolar. Hadiah untuk jackpot didistribusikan diantara semua pemain yg menang selama produk yang sama. Sesuai dengan jumlah duit nyata yang dipertaruhkan pada mesin, pembayaran jackpot dapat menyesar.

Dalam produk slot online, bankroll adalah yang mendanai slot yang disiarkan langsung permainan mesin. Bankroll adalah bentuk uang tunai secara telah dibayar di muka. Untuk mengasaskan, Anda biasanya kudu memasukkan jumlah yang Anda inginkan. Setelah Kita memasang modal, Anda dapat menggunakan uang itu untuk membayar permainan mesin slot yang sebenarnya dan memasang taruhan di dalam hasil putaran. Begitu permainan telah dibayar dan Anda unggul, Anda akan dikreditkan dengan kemenangan Kamu dan uang Kita akan dikeluarkan daripada akun Anda.

Untuk memastikan kalau Anda memiliki kepandaian paling menyenangkan di mesin slot Kita Sangat penting buat memilih mesin yg memiliki persentase pembayaran tinggi. Persentase pengembalian adalah jumlah kelebihan yang harus Anda hasilkan untuk membela jumlah uang yang Anda mainkan. Idealnya, semakin menggunung pukulan yang kudu Anda pukul utk menang, semakin raksasa peluang Anda utk memukulnya. Persentase pembayaran yang tidak pas tinggi bisa berarti Anda kalah kian dari yang Kita harapkan.

Kecuali simbol yang menunjukkan simbol kemenangan produk slot online Ada angka yang muncul di layar. Angka-angka ini dapat membantu Anda memutuskan mana yang merupakan pendanaan terbaik. Jika Kita dapat mengidentifikasi investasi yang paling mujur, Anda dapat memilih untuk bertaruh jumlah daripada bertaruh di dalam simbol lain.

Game slot online yang menawarkan bagian pembayaran tinggi ialah pilihan yang rupawan. strategi. Orang sering mencoba untuk meningkatkan kemenangan mereka melalui lebih banyak putaran. Strategi ini mampu menjadi bumerang pada arti bahwa tingkat pengembalian yang tinggi menarik lebih banyak pemain yang akan mendapat untung dari Anda. Cara terkemuka untuk menghindarinya adalah dengan bertaruh di mesin dengan persentase pembayaran yang lebih rendah sehingga Anda meminimalkan risiko serta memaksimalkan keuntungan Kita.


Black Women at Greater Risk for Lymphedema After Breast Cancer Surgery

By Cara Murez
HealthDay Reporter

TUESDAY, Dec. 7, 2021 (HealthDay News) — A condition called lymphedema is a well-known side effect of breast cancer treatment that can lead to swelling in the arms and legs.

New research suggests that Black women experience are at more than three times the risk of this painful issue compared to white women.

“Lymphedema worsens quality of life for breast cancer patients,” said the study’s lead author, Dr. Andrea Barrio. She is an associate attending physician in the breast service department at Memorial Sloan Kettering Cancer Center in New York City.

Understanding the links between race, cancer treatment and the effects of treatment could ultimately help improve quality of life for breast cancer patients and survivors, Barrio said in a news release from the San Antonio Breast Cancer Symposium.

Lymphedema has been somewhat overlooked in the research arena, said Dr. Stephanie Bernik, an associate professor of breast surgery at Icahn School of Medicine at Mount Sinai in New York City. She was not involved in the study.

“This study hints at some of the possible reasons for racial disparity, as women with lymphedema were more likely to undergo radiation therapy and chemotherapy before surgery,” Bernik said.

“Black women with lymphedema were also more likely to have a higher BMI [body mass index], a known risk factor for developing lymphedema. There very well may also be a genetic component but more study needs to be directed to the root causes of the problem,” she added.

For the study, the researchers enrolled more than 300 breast cancer patients and used arm volume measurements rather than more common self-reported experiences or diagnosis codes.

The patients had undergone axillary lymph node dissection — surgical removal of lymph nodes — between November 2016 and March 2020.

The researchers measured patients’ arm volume at baseline, after their surgery and at six-month intervals. The study defined lymphedema as relative volume change of 10% or greater from the baseline.

At 24 months of follow-up, about 25% of the women had developed lymphedema. Black women had a 3.5-fold increased risk of lymphedema compared to white women, the findings showed.

Hispanic women also had greater odds of lymphedema than white women, with a threefold increased risk. The study authors noted that the Hispanic study population was small (just 6%), so further study would be necessary to confirm these findings.

The type of treatment seemed to make a difference. Women who had received neoadjuvant chemotherapy — chemo before surgery — and then lymph node removal were twice as likely to develop lymphedema as their counterparts who had upfront surgery followed by axillary lymph node dissection, the study found.

Barrio said other research has proven that Black women are often diagnosed with later-stage breast cancer. They are thus more likely to need the axillary surgery that can increase risk for lymphedema. Still, Black race was the strongest predictor of lymphedema development.

Other factors associated with a higher risk of lymphedema were older age and increasing time from surgery.

The findings will be presented this week at the breast cancer symposium. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute has more on lymphedema.

SOURCES: Stephanie Bernik, MD, chief, breast surgery, Mount Sinai West and associate professor, breast surgery, Icahn School of Medicine at Mount Sinai, New York City; San Antonio Breast Cancer Symposium, news release, Dec. 7, 2021

Victoria Derbyshire says overcoming breast cancer ‘changed her life’

Victoria Derbyshire says overcoming breast cancer ‘changed her life’ after she thought she was ‘going to die’ from the illness. 

The journalist,  53,  announced she had been diagnosed with breast cancer in 2015, undergoing a mastectomy and reconstructive surgery soon after. 

Following 301 days of treatment including six sessions of chemotherapy and 30 sessions of radiotherapy, the mother-of-two was given the all clear with an 11 per cent chance of the cancer recurring.  

In a new interview with Stella Magazine, Victoria, who lives in Surrey with her husband Mark and two sons, spoke about how her diagnosis inspired her to finally marry her partner. 

Victoria Derbyshire, pictured in London last year, says overcoming breast cancer ‘changed her life’ after she thought she was ‘going to die’ from the illness

In January 2020, it was announced that the broadcaster's eponymous show was being cancelled by the BBC because the cost of doing it on a 'linear channel' were too high

In January 2020, it was announced that the broadcaster’s eponymous show was being cancelled by the BBC because the cost of doing it on a ‘linear channel’ were too high

‘It changed my life’, said Victoria.

‘The joy and happiness I felt at being alive was amazing. I say yes to so many things now.’ 

The presenter added that beating the illness encouraged her to strip off in front of an audience two years after her mastectomy for ITV’s The Real Full Monty and compete in I’m A Celebrity in 2020.  

It was her illness that spurred her decision to marry Mark after 17 years together in 2018. He had proposed before she was pregnant with her first child – however the two never actually tied the knot. 

‘After my diagnosis, I’d said, “If we get through this I would like to get married, but I don’t want you to do it if it’s only because you feel sorry for me.”, she explained. 

Victoria, who lives in Surrey with her husband Mark and two sons, spoke about how her diagnosis inspired her to finally marry her partner (pictured)

Victoria, who lives in Surrey with her husband Mark and two sons, spoke about how her diagnosis inspired her to finally marry her partner (pictured) 

‘It was weird to finally start calling him my husband, but amazing to get married at 49. I feel more complete now.’   

Victoria was 46 when she noticed an abnormality in one of her nipples while she was getting ready for bed one evening, quickly booking an emergency GP appointment. 

She underwent gruelling treatment including chemotherapy and radio therapy  before doctors told her she was in remission five years ago

In January 2020, it was announced that the broadcaster’s eponymous show was being cancelled by the BBC because the cost of doing it on a ‘linear channel’ were too high.

Victoria says that while she was ‘gutted’ the show had been axed, her battle with breast cancer gave her a ‘different perspective’ and allowed her to cope with the loss of her show.

The broadcaster opened up about the loss of her show last year in an interview with Woman & Home magazine, insisting: ‘It was gutting when I was told I was losing my TV show but having gone through breast cancer I was able to put it in perspective,’ she said.

Mother-of-two Victoria, pictured in 2018, announced she had been diagnosed with breast cancer in 2015, undergoing a mastectomy and reconstructive surgery soon after

Mother-of-two Victoria, pictured in 2018, announced she had been diagnosed with breast cancer in 2015, undergoing a mastectomy and reconstructive surgery soon after

‘I was lucky I still had a job in a pandemic and I have come through something where I could have died.’   

Immediately after being diagnosed, Victoria says she didn’t want to tell Mark or her sons, who were 11 and eight at the time, straight away, saying she went into ‘practical mode’ instantly.  

‘I thought very early on I was going to die. Mark and I went to a little park and really cried and hugged. Saying I might die is such a weird thing to say aloud. We had no idea then if it was treatable. Once the tears were over, we went into practical mode, telling work, friends and family.’  

One of the toughest things about Victoria’s battle with cancer was losing her hair to chemotherapy, something she says was more challenging than losing her breast.

The broadcaster had a wig made because she ‘didn’t want people to feel sorry for her’.

Her treatment lasted 301 days and on the same day she left the hospital, Victoria travelled to Glasgow to present a debate for BBC One.

That weekend she celebrated by holding a party with her loved ones – complete with a cake hailing her ‘Victorious Victoria’ made by her husband. 

Debbie McGee admits crying after breast cancer diagnosis because ‘Paul wasn’t there’ | Celebrity News | Showbiz & TV

After a while, Debbie said she tried to just “get on with life”.

She explained it was similar to when she was dealing with Paul and that there was no point “sitting at home crying.”

Debbie explained to Mail Online in November 2021 that after she appeared on Strictly, her life turned around following her husband’s death and she became a much more energetic person.

She revealed she was finally happy again after five years of sorrow at the time, and told The Mirror he was ready to meet someone new.

Petikan bermain mesin slot di Kasino Daring

Banyak orang-orang percaya bahwa permainan slot online dalam situs kasino online memberikan keuntungan khusus kepada konsumen. Tapi, ada banyak sepak-terjang keamanan yang harus Anda ambil saat memainkan permainan slot favorit Anda pada World Wide Web. Pemain slot online dapat menikmati keceriaan sangat saat bermain di rumah karakter dan nyaman itu sendiri. Kemudahan menutup dengan kartu penghargaan, transfer elektronik, dan uang tunai nyata untuk bermain hanyalah beberapa keuntungan secara dapat dinikmati tokoh saat memainkan permainan slot favorit tersebut di internet.

Ada berbagai macam permainan slot online yang dapat ditemukan di bermacam-macam situs judi. Kamu dapat memilih khilaf satu yang memikat bagi Anda serta lokasi Anda tinggal. Ada kasino secara menerima kartu ponten utama dan menutup dengan transfer elektronik atau uang tunai. Banyak kasino online tersedia dua puluh empat jam sehari dan tujuh tarikh semaine.

Jumlah orang menikmati sajian slot online olehkarena itu fakta bahwa permainan ini memberikan alternatif yang layak buat perjudian di mana Anda dapat mempertunjukkan game favorit Anda sambil menikmati pekerjaan atau kehidupan perseorangan Anda. Dimungkinkan saja untuk bermain game slot saat Anda bepergian ke dan dari tempat komitmen. Tidak perlu merebut minuman beralkohol serta berjudi secara bertumbukan. Ini juga putusan biaya, karena Kamu tidak perlu menimbulkan uang untuk besi atau parkir.

Permainan kasino online memiliki karakteristik susulan yang membuatnya amat populer di tataran pemain. Salah satu fitur ini adalah kemungkinan untuk permainan mesin slot secara permainan bonus. Beberapa kasino online menghapuskan promosi dan bonus tambahan kepada pemain yang memainkan perangkat slot dengan sajian bonus. Permainan kasino online menawarkan kepandaian perjudian premium menurut para penjudi, antarmuka yang nyaman, jackpot tinggi, insentif serta promosi yang acap. Selain itu, sajian kasino memiliki bermacam-macam karakteristik tambahan yang menjadikannya favorit untuk pemain.

Alat slot di kasino online memberikan kepandaian tak terlupakan rezeki antarmuka yang ramah pengguna, menakjubkan grafis, dan permainan secara sangat. Para pengelola dan pengembang mempergunakan teknologi paling selit belit untuk menciptakan visual dan efek suara yang menarik. Tersebut telah menciptakan bermacam-macam antarmuka pengguna untuk memungkinkan pemain memainkan game di berbagai perangkat dan utama layar yang berputar antara menengah dan kecil. game deposit pulsa sebab itu, mudah untuk pemain untuk memilih perangkat game secara paling cocok buat mereka.

Permainan multipemain adalah puaka lain dari permainan slot online. Tersebut memungkinkan pemain bermain bersama pemain beda meskipun tidak terdapat pemain lain dalam kasino. Ini berguna Anda akan dijamin cenderung uang daripada paylines yang disediakan oleh kasino beda. Beberapa kasino daring menawarkan jackpot progresif yang memungkinkan Kita memenangkan sejumlah gede uang setelah memainkan sejumlah putaran khusus.

Slot daring adalah opsi kekasih bagi pemain yg menyukai kasino karena Payline murah menawan hati yang ditawarkan kasino. Ada berbagai pilihan pembayaran yang ditawarkan oleh kasino online. Salah satu yang paling diminati ialah penggunaan kartu ponten. PayPal adalah opsi lain yang dapat digunakan untuk berbuat pembayaran dengan tenang dan aman di beberapa kasino. Kita dapat bermain tanpa khawatir harus membalas sejumlah besar uang atau berurusan dengan masalah pembayaran on line.

Mesin video poker menjadi semakin terkenal di kasino online. Mesin video poker ini menghapuskan pemain grafis yg sangat baik & trek audio yang bagus, yang menumbuhkan pengalaman video poker. Video poker merupakan salah satu sajian yang paling banyak dimainkan di kasino online ini. Kasino ini menyediakan slot gratis tempat Kamu dapat menguji spesialisasi Anda sebelum bisa bertaruh dengan uang sungguhan.